Hesitancy around low-dose CT screening for lung cancer

Dickson, Jennifer; Horst, Carolyn; Nair, Arjun; Tisi, Sophie; Prendecki, Ruth; Janes, SM

doi:10.1016/j.annonc.2021.09.008

Cited by 36 publications

(34 citation statements)

References 62 publications

(65 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These may help more medical workers suggest high-risk residents to undergo lung cancer screening with LDCT. Several studies reported that the main barriers for medical workers to recommend residents to undergo LDCT screening were patients’ cost, potential harm of false-positive findings or patients’ lack of knowledge on the risk of lung cancer 23 26 27. This was partially similar to our findings, where our study showed that a high proportion of false-positive results and exposure to radiation were the main reasons medical workers did not recommend LDCT screening.…”

Section: Discussionsupporting

confidence: 85%

Level of knowledge on low-dose CT lung cancer screening in Sichuan province, China: a cross-sectional study

Luo

Tao

et al. 2022

BMJ Open

View full text Add to dashboard Cite

ObjectivesLow-dose CT (LDCT) can help determine the early stage of lung cancer and reduce mortality. However, knowledge of lung cancer and lung cancer screening among community residents and medical workers, and potential factors that may affect medical institutions to set up LDCT are limited.DesignA cross-sectional study was conducted in Sichuan province, China, in 2021. Community residents, medical workers and medical institutions were randomly selected, and participants responded to related questionnaires. Knowledge of lung cancer and LDCT lung cancer screening was evaluated. Data analyses were performed using SAS V.9.4.ResultsA total of 35 692 residents, 6350 medical workers and 81 medical institutions were recruited; 4.05% of the residents were very familiar with lung cancer and 37.89% were (completely) unfamiliar. Characteristics, such as age and level of education, were significantly related to residents who were very familiar with lung cancer. Furthermore, 22.87% of the residents knew that LDCT can effectively screen for early-stage lung cancer, which was correlated with smoking (OR 1.1300; 95% CI 1.0540 to 1.2110; p=0.006) and family history of cancer (OR 1.2210; 95% CI 1.1400 to 1.3080; p<0.0001); 66.06% of medical workers believed that LDCT can detect early-stage lung cancer. Technicians and nurses were less knowledgeable than doctors about whether LDCT can effectively screen for early-stage lung cancer (OR 0.6976; 95% CI 0.5399 to 0.9015; p=0.0059 and OR 0.6970; 95% CI 0.5718 to 0.8496; p=0.0004, respectively). Setting up LDCT in medical institutions was related to grade, administrative rank, number of hospital beds that opened and total number of medical workers.ConclusionsThe knowledge of lung cancer in residents is relatively low, and the knowledge of LDCT in screening (early-stage) lung cancer needs to be improved both in residents and medical workers. Possible factors that affect medical institutions to set up LDCT may need to be incorporated.

show abstract

Section: Discussionsupporting

confidence: 85%

Level of knowledge on low-dose CT lung cancer screening in Sichuan province, China: a cross-sectional study

Luo

Tao

et al. 2022

BMJ Open

View full text Add to dashboard Cite

show abstract

“…However, the detection and diagnosis of lung cancer at an early stage is still challenging because of the lack of clinical manifestations and specific biomarkers. 2 Annual low-dose chest computed tomography (LDCT) screening has been proven to substantially reduce lung cancer specific mortality. 3 , 4 However, the application of LDCT screening is challenging in multiple aspects.…”

Section: Introductionmentioning

confidence: 99%

“…High costs, radiation exposure, and a high false-positive rate hinder the application of LDCT for large-scale screening. 2 , 5 A highly accurate and non-invasive tool for lung cancer screening is urgently warranted.…”

Section: Introductionmentioning

confidence: 99%

Identification of lung cancer breath biomarkers based on perioperative breathomics testing: A prospective observational study

et al. 2022

View full text Add to dashboard Cite

“…This disease leads to more deaths in contrast to breast, cervical, and colorectal cancer combined [ 2 ]. When asymptomatic early (I/II) disease with potentially curative treatment, >70% of cases diagnosed with advanced (III/IV) disease have rarely curative treatment, highly contributing to undesirable prognostic outcomes, with only 16.2% of cases diagnosed with the disease alive at 5 years [ 3 ]. About 85% of tumors are diagnosed as non-small-cell lung cancer (NSCLC), with lung adenocarcinoma (LUAD) as the most prevalent subtype [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Definition of a Novel Cuproptosis-Relevant lncRNA Signature for Uncovering Distinct Survival, Genomic Alterations, and Treatment Implications in Lung Adenocarcinoma

Wang

Yao

Dong

et al. 2022

Journal of Immunology Research

View full text Add to dashboard Cite

Objective. Cuproptosis is a newly discovered copper-independent cell death modality, and limited evidence suggests the critical implications in human cancers. Nonetheless, the clinical impacts of cuproptosis-relevant lncRNAs in lung adenocarcinoma (LUAD) remain largely ill-defined. The present study was aimed at defining a cuproptosis-relevant lncRNA signature for LUAD and discuss the clinical utility. Methods. We collected transcriptome expression profiling, clinical information, somatic mutation, and copy number variations from TCGA-LUAD cohort retrospectively. The genetic alterations of cuproptosis genes were systematically assessed across LUAD, and cuproptosis-relevant lncRNAs were screened for defining a LASSO prognostic model. Genomic alterations, immunological and stemness features, and therapeutic sensitivity were studied with a series of computational approaches. Results. Cuproptosis genes displayed aberrant expression and widespread genomic alterations across LUAD, potentially modulated by m6A/m5C/m1A RNA modification mechanisms. We defined a cuproptosis-relevant lncRNA signature, with a reliable efficacy in predicting clinical outcomes. High-risk subset displayed higher somatic mutations, CNVs, TMB, SNV neoantigens, aneuploidy score, CTA score, homologous recombination defects, and intratumor heterogeneity, cytolytic activity, CD8+ T effector, and antigen processing machinery, proving that this subset might benefit from immunotherapy. Increased stemness indexes and activity of oncogenic pathways might contribute to undesirable prognostic outcomes for high-risk subset. Additionally, high-risk patients generally exhibited higher response to chemotherapeutic agents (cisplatin, etc.). We also predicted several small molecule compounds (GSK461364, KX2-391, etc.) for treating this subset. Conclusion. Accordingly, this cuproptosis-relevant lncRNA signature offers an efficient approach to identify and characterize diverse prognosis, genomic alterations, and treatment outcomes in LUAD, thus potentially assisting personalized therapy.

show abstract

Hesitancy around low-dose CT screening for lung cancer

Cited by 36 publications

References 62 publications

Level of knowledge on low-dose CT lung cancer screening in Sichuan province, China: a cross-sectional study

Level of knowledge on low-dose CT lung cancer screening in Sichuan province, China: a cross-sectional study

Identification of lung cancer breath biomarkers based on perioperative breathomics testing: A prospective observational study

Definition of a Novel Cuproptosis-Relevant lncRNA Signature for Uncovering Distinct Survival, Genomic Alterations, and Treatment Implications in Lung Adenocarcinoma

Contact Info

Product

Resources

About